Mallinckrodt Pharmaceuticals, based in Dublin, Ireland with U.S. headquarters in St. Louis, Missouri, produces specialty pharmaceutical products including generic drugs and imaging agents. Mallinckrodt, LLC manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions. It offers addiction treatment products, and specialty generics and pharmaceuticals; and active pharmaceutical ingredients, including medicinal narcotics, acetaminophen/paracetamol, stearates, phosphates, and peptides, as well as analytical research samples for pharmaceutical companies and analytical laboratories. The company also supplies medical isotope technetium-99m; and radiopharmaceuticals, and contrast media and delivery systems. It serves customers in the United States and internationally. The company was originally founded in 1867 and is based in Hazelwood, Missouri. Mallinckrodt Pharmaceuticals, based in Dublin, Ireland hasU.S. headquarters in St. Louis, Missouri, produces specialty pharmaceutical products including generic drugs and imaging agents. Recent histroy: In 2000 Tyco International acquired Mallinckrodt. Seven years later, in 2007 Tyco Healthcare spun off and becomes Covidien, an independent company [9] The healthcare business units were spun off under the name Covidien. In 2011 Covidien spun off Mallinckrodt Pharmaceuticals as a standalone public company. Shortly after acquiring CNS Therapeutics in 2012, Mallinckrodt spun off from Covidien and begins trading under ticker symbol MNK
